ID   ACHA4_RAT               Reviewed;         630 AA.
AC   P09483; O35769;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 3.
DT   02-OCT-2024, entry version 198.
DE   RecName: Full=Neuronal acetylcholine receptor subunit alpha-4;
DE   Flags: Precursor;
GN   Name=Chrna4; Synonyms=Acra4;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-4-1), AND NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 5-630 (ISOFORM ALPHA-4-2).
RC   STRAIN=Sprague-Dawley; TISSUE=Hippocampus, and Hypothalamus;
RX   PubMed=3829125; DOI=10.1016/0092-8674(87)90705-7;
RA   Goldman D.J., Deneris E.S., Luyten W., Kochhar A., Patrick J.,
RA   Heinemann S.F.;
RT   "Members of a nicotinic acetylcholine receptor gene family are expressed in
RT   different regions of the mammalian central nervous system.";
RL   Cell 48:965-973(1987).
RN   [2]
RP   SEQUENCE REVISION.
RA   Hartley M., Goldman D.J., Heinemann S.F.;
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-4-2).
RA   Boulter J., Deneris E.S., Evans K., Heinemann S.F.;
RL   Submitted (JUN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   PROTEIN SEQUENCE OF 31-47.
RX   PubMed=3609304; DOI=10.1016/0014-5793(87)80272-7;
RA   Whiting P., Esch F., Shimasaki S., Lindstrom J.;
RT   "Neuronal nicotinic acetylcholine receptor beta-subunit is coded for by the
RT   cDNA clone alpha 4.";
RL   FEBS Lett. 219:459-463(1987).
RN   [5]
RP   SUBUNIT.
RX   PubMed=15929983; DOI=10.1074/jbc.m504229200;
RA   Dutertre S., Nicke A., Lewis R.J.;
RT   "Beta2 subunit contribution to 4/7 alpha-conotoxin binding to the nicotinic
RT   acetylcholine receptor.";
RL   J. Biol. Chem. 280:30460-30468(2005).
RN   [6]
RP   PALMITOYLATION AT CYS-273, AND SUBCELLULAR LOCATION.
RX   PubMed=22593584; DOI=10.1074/jbc.m111.328294;
RA   Amici S.A., McKay S.B., Wells G.B., Robson J.I., Nasir M., Ponath G.,
RA   Anand R.;
RT   "A highly conserved cytoplasmic cysteine residue in the alpha4 nicotinic
RT   acetylcholine receptor is palmitoylated and regulates protein expression.";
RL   J. Biol. Chem. 287:23119-23127(2012).
RN   [7]
RP   MUTAGENESIS OF 219-THR--ARG-242; 220-TYR--ARG-223 AND ARG-223.
RX   PubMed=22751014; DOI=10.1096/fj.12-204487;
RA   Kim H.W., McIntosh J.M.;
RT   "alpha6 nAChR subunit residues that confer alpha-conotoxin BuIA
RT   selectivity.";
RL   FASEB J. 26:4102-4110(2012).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-428, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: After binding acetylcholine, the AChR responds by an
CC       extensive change in conformation that affects all subunits and leads to
CC       opening of an ion-conducting channel across the plasma membrane
CC       permeable to sodium ions.
CC   -!- SUBUNIT: Neuronal AChR is composed of two different types of subunits:
CC       alpha and beta. Alpha-4 subunit can be combined to beta-2 or beta-4 to
CC       give rise to functional receptors, complexes with beta-2 may be
CC       heteropentamers. Interacts with RIC3; which is required for proper
CC       folding and assembly. Interacts with LYPD6. The heteropentamer alpha-4-
CC       beta-2 interacts with alpha-conotoxins PnIA, GID and MII
CC       (PubMed:15929983). {ECO:0000250|UniProtKB:P43681,
CC       ECO:0000269|PubMed:15929983}.
CC   -!- INTERACTION:
CC       P09483; P20420: Chrna5; NbExp=6; IntAct=EBI-7842410, EBI-10828372;
CC       P09483; P12390: Chrnb2; NbExp=6; IntAct=EBI-7842410, EBI-9008812;
CC       P09483; P12392: Chrnb4; NbExp=4; IntAct=EBI-7842410, EBI-9008856;
CC   -!- SUBCELLULAR LOCATION: Postsynaptic cell membrane
CC       {ECO:0000269|PubMed:22593584}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:22593584}. Cell membrane
CC       {ECO:0000269|PubMed:22593584}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:22593584}. Cell membrane
CC       {ECO:0000269|PubMed:22593584}; Lipid-anchor
CC       {ECO:0000269|PubMed:22593584}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Alpha-4-1;
CC         IsoId=P09483-1; Sequence=Displayed;
CC       Name=Alpha-4-2;
CC         IsoId=P09483-2; Sequence=VSP_000074;
CC   -!- TISSUE SPECIFICITY: In various regions of the central nervous system.
CC   -!- MISCELLANEOUS: The nAChR composed of alpha-4 and beta-2 subunits does
CC       not bind the conotoxin BuIA. {ECO:0000269|PubMed:22751014}.
CC   -!- SIMILARITY: Belongs to the ligand-gated ion channel (TC 1.A.9) family.
CC       Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha-4/CHRNA4 sub-
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M15682; AAA41676.1; -; mRNA.
DR   EMBL; L31620; AAC97071.1; -; mRNA.
DR   EMBL; AF007212; AAB64439.1; -; mRNA.
DR   RefSeq; NP_077330.1; NM_024354.1.
DR   AlphaFoldDB; P09483; -.
DR   SMR; P09483; -.
DR   ComplexPortal; CPX-170; Neuronal nicotinic acetylcholine receptor complex, 2xalpha4-3xbeta2.
DR   ComplexPortal; CPX-171; Neuronal nicotinic acetylcholine receptor complex, 3xalpha4-2xbeta2.
DR   ComplexPortal; CPX-215; Neuronal nicotinic acetylcholine receptor complex, alpha4-alpha5-beta2.
DR   ComplexPortal; CPX-219; Neuronal nicotinic acetylcholine receptor complex, alpha4-beta4.
DR   CORUM; P09483; -.
DR   IntAct; P09483; 6.
DR   MINT; P09483; -.
DR   STRING; 10116.ENSRNOP00000073967; -.
DR   BindingDB; P09483; -.
DR   ChEMBL; CHEMBL307; -.
DR   DrugCentral; P09483; -.
DR   GuidetoPHARMACOLOGY; 465; -.
DR   GlyCosmos; P09483; 3 sites, No reported glycans.
DR   GlyGen; P09483; 3 sites.
DR   iPTMnet; P09483; -.
DR   PhosphoSitePlus; P09483; -.
DR   SwissPalm; P09483; -.
DR   PaxDb; 10116-ENSRNOP00000009041; -.
DR   GeneID; 25590; -.
DR   KEGG; rno:25590; -.
DR   UCSC; RGD:2346; rat. [P09483-1]
DR   AGR; RGD:2346; -.
DR   CTD; 1137; -.
DR   RGD; 2346; Chrna4.
DR   eggNOG; KOG3645; Eukaryota.
DR   InParanoid; P09483; -.
DR   OrthoDB; 5489962at2759; -.
DR   PhylomeDB; P09483; -.
DR   Reactome; R-RNO-629587; Highly sodium permeable postsynaptic acetylcholine nicotinic receptors.
DR   Reactome; R-RNO-629594; Highly calcium permeable postsynaptic nicotinic acetylcholine receptors.
DR   Reactome; R-RNO-629597; Highly calcium permeable nicotinic acetylcholine receptors.
DR   PRO; PR:P09483; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005892; C:acetylcholine-gated channel complex; IDA:RGD.
DR   GO; GO:0098981; C:cholinergic synapse; IDA:SynGO.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0098691; C:dopaminergic synapse; ISO:RGD.
DR   GO; GO:0009897; C:external side of plasma membrane; ISO:RGD.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0099634; C:postsynaptic specialization membrane; IDA:SynGO.
DR   GO; GO:0098793; C:presynapse; ISO:RGD.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:SynGO.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0042166; F:acetylcholine binding; IDA:RGD.
DR   GO; GO:0015464; F:acetylcholine receptor activity; ISO:RGD.
DR   GO; GO:0022848; F:acetylcholine-gated monoatomic cation-selective channel activity; IDA:RGD.
DR   GO; GO:1901363; F:heterocyclic compound binding; IDA:RGD.
DR   GO; GO:0005216; F:monoatomic ion channel activity; ISO:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0050997; F:quaternary ammonium group binding; IDA:RGD.
DR   GO; GO:1904315; F:transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential; IDA:SynGO.
DR   GO; GO:0095500; P:acetylcholine receptor signaling pathway; ISO:RGD.
DR   GO; GO:0042113; P:B cell activation; ISO:RGD.
DR   GO; GO:0035095; P:behavioral response to nicotine; ISO:RGD.
DR   GO; GO:0006816; P:calcium ion transport; ISO:RGD.
DR   GO; GO:0050890; P:cognition; ISO:RGD.
DR   GO; GO:0006281; P:DNA repair; ISO:RGD.
DR   GO; GO:0035640; P:exploration behavior; ISO:RGD.
DR   GO; GO:0060080; P:inhibitory postsynaptic potential; ISO:RGD.
DR   GO; GO:0007626; P:locomotory behavior; ISO:RGD.
DR   GO; GO:0051899; P:membrane depolarization; ISO:RGD.
DR   GO; GO:0050877; P:nervous system process; ISO:RGD.
DR   GO; GO:0019228; P:neuronal action potential; ISO:RGD.
DR   GO; GO:0099171; P:presynaptic modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0014059; P:regulation of dopamine secretion; ISO:RGD.
DR   GO; GO:0042391; P:regulation of membrane potential; ISO:RGD.
DR   GO; GO:0007585; P:respiratory gaseous exchange by respiratory system; ISO:RGD.
DR   GO; GO:1905144; P:response to acetylcholine; IDA:RGD.
DR   GO; GO:0001666; P:response to hypoxia; ISO:RGD.
DR   GO; GO:0035094; P:response to nicotine; ISO:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; ISO:RGD.
DR   GO; GO:0019233; P:sensory perception of pain; ISO:RGD.
DR   GO; GO:0007165; P:signal transduction; ISO:RGD.
DR   GO; GO:0007271; P:synaptic transmission, cholinergic; IMP:RGD.
DR   CDD; cd19064; LGIC_TM_nAChR; 1.
DR   Gene3D; 2.70.170.10; Neurotransmitter-gated ion-channel ligand-binding domain; 1.
DR   Gene3D; 1.20.58.390; Neurotransmitter-gated ion-channel transmembrane domain; 2.
DR   InterPro; IPR006202; Neur_chan_lig-bd.
DR   InterPro; IPR036734; Neur_chan_lig-bd_sf.
DR   InterPro; IPR006201; Neur_channel.
DR   InterPro; IPR036719; Neuro-gated_channel_TM_sf.
DR   InterPro; IPR038050; Neuro_actylchol_rec.
DR   InterPro; IPR006029; Neurotrans-gated_channel_TM.
DR   InterPro; IPR018000; Neurotransmitter_ion_chnl_CS.
DR   InterPro; IPR002394; Nicotinic_acetylcholine_rcpt.
DR   NCBIfam; TIGR00860; LIC; 1.
DR   PANTHER; PTHR18945:SF401; NEURONAL ACETYLCHOLINE RECEPTOR SUBUNIT ALPHA-4; 1.
DR   PANTHER; PTHR18945; NEUROTRANSMITTER GATED ION CHANNEL; 1.
DR   Pfam; PF02931; Neur_chan_LBD; 1.
DR   Pfam; PF02932; Neur_chan_memb; 1.
DR   PRINTS; PR00254; NICOTINICR.
DR   PRINTS; PR00252; NRIONCHANNEL.
DR   SUPFAM; SSF90112; Neurotransmitter-gated ion-channel transmembrane pore; 1.
DR   SUPFAM; SSF63712; Nicotinic receptor ligand binding domain-like; 1.
DR   PROSITE; PS00236; NEUROTR_ION_CHANNEL; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; Signal; Synapse;
KW   Transmembrane; Transmembrane helix; Transport.
FT   SIGNAL          1..30
FT                   /evidence="ECO:0000255"
FT   CHAIN           31..630
FT                   /note="Neuronal acetylcholine receptor subunit alpha-4"
FT                   /id="PRO_0000000354"
FT   TOPO_DOM        32..249
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        250..270
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        279..299
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        313..333
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        334..604
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        605..625
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   REGION          418..463
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          505..526
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         428
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         542
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O70174"
FT   MOD_RES         545
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O70174"
FT   LIPID           273
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:22593584"
FT   CARBOHYD        59
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        109
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        176
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        163..177
FT                   /evidence="ECO:0000250"
FT   DISULFID        227..228
FT                   /note="Associated with receptor activation"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         629..630
FT                   /note="AC -> GMI (in isoform Alpha-4-2)"
FT                   /evidence="ECO:0000303|PubMed:3829125, ECO:0000303|Ref.3"
FT                   /id="VSP_000074"
FT   MUTAGEN         219..240
FT                   /note="TYNTRKYECCAEIYPDITYAFI->YKHDIKYNCCEEIYTDITYSFY:
FT                   >10000-fold increase in inhibition of alpha-4-beta-2 nAChR
FT                   by the conotoxin BuIA."
FT                   /evidence="ECO:0000269|PubMed:22751014"
FT   MUTAGEN         220..223
FT                   /note="YNTR->KHDI: >1700-fold increase in inhibition of
FT                   alpha-4-beta-2 nAChR by the conotoxin BuIA."
FT                   /evidence="ECO:0000269|PubMed:22751014"
FT   MUTAGEN         223
FT                   /note="R->I: >10-fold increase in inhibition of alpha-4-
FT                   beta-2 nAChR by the conotoxin BuIA."
FT                   /evidence="ECO:0000269|PubMed:22751014"
FT   CONFLICT        1..4
FT                   /note="MANS -> MEIGGPGA (in Ref. 1; AAA41676)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        6
FT                   /note="T -> P (in Ref. 3; AAB64439)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        58
FT                   /note="A -> G (in Ref. 1; AAA41676 and 3; AAB64439)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        196
FT                   /note="M -> I (in Ref. 1; AAA41676 and 3; AAB64439)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        301
FT                   /note="Missing (in Ref. 1; AAA41676/AAC97071 and 3;
FT                   AAB64439)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   630 AA;  70193 MW;  1DFFC9E1378E5417 CRC64;
     MANSGTGAPP PLLLLPLLLL LGTGLLPASS HIETRAHAEE RLLKRLFSGY NKWSRPVANI
     SDVVLVRFGL SIAQLIDVDE KNQMMTTNVW VKQEWHDYKL RWDPGDYENV TSIRIPSELI
     WRPDIVLYNN ADGDFAVTHL TKAHLFYDGR VQWTPPAIYK SSCSIDVTFF PFDQQNCTMK
     FGSWTYDKAK IDLVSMHSRV DQLDFWESGE WVIVDAVGTY NTRKYECCAE IYPDITYAFI
     IRRLPLFYTI NLIIPCLLIS CLTVLVFYLP SECGEKVTLC ISVLLSLTVF LLLITEIIPS
     PTSLVIPLIG EYLLFTMIFV TLSIVITVFV LNVHHRSPRT HTMPAWVRRV FLDIVPRLLF
     MKRPSVVKDN CRRLIESMHK MANAPRFWPE PVGEPGILSD ICNQGLSPAP TFCNPTDTAV
     ETQPTCRSPP LEVPDLKTSE VEKASPCPSP GSCPPPKSSS GAPMLIKARS LSVQHVPSSQ
     EAAEDGIRCR SRSIQYCVSQ DGAASLADSK PTSSPTSLKA RPSQLPVSDQ ASPCKCTCKE
     PSPVSPVTVL KAGGTKAPPQ HLPLSPALTR AVEGVQYIAD HLKAEDTDFS VKEDWKYVAM
     VIDRIFLWMF IIVCLLGTVG LFLPPWLAAC
//
